Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
Anticancer Res
; 38(11): 6565-6569, 2018 Nov.
Article
in En
| MEDLINE
| ID: mdl-30396987
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Taxoids
/
Antibodies, Monoclonal, Humanized
/
Trastuzumab
Type of study:
Observational_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Anticancer Res
Year:
2018
Document type:
Article
Affiliation country:
Greece
Country of publication:
Greece